Iron Chelators in Treatment of Iron Overload

被引:68
|
作者
Entezari, Sarina [1 ]
Haghi, Seyedeh Mona [2 ]
Norouzkhani, Narges [3 ]
Sahebnazar, Barsa [4 ]
Vosoughian, Fatemeh [5 ]
Akbarzadeh, Diba [5 ]
Islampanah, Muhammad [6 ]
Naghsh, Navid [7 ]
Abbasalizadeh, Mohammad [8 ]
Deravi, Niloofar [5 ]
机构
[1] Shahid Beheshti Univ Med Sci, Student Res Comm, Sch Allied Med Sci, Tehran, Iran
[2] Mashhad Univ Med Sci, Student Res Comm, Sch Pharm, Mashhad, Iran
[3] Mashhad Univ Med Sci, Fac Med, Dept Med Informat, Mashhad, Iran
[4] Fasa Univ Med Sci, Student Res Comm, Fasa, Iran
[5] Shahid Beheshti Univ Med Sci, Student Res Comm, Sch Med, Tehran, Iran
[6] Mashhad Univ Med Sci, Fac Med, Mashhad, Iran
[7] Shahid Sadoughi Univ Med Sci, Dept Pharm, Yazd, Iran
[8] Tabriz Univ Med Sci, Fac Med, Tabriz, Iran
关键词
BETA-THALASSEMIA MAJOR; RANDOMIZED CONTROLLED-TRIAL; SICKLE-CELL-DISEASE; COMBINED ORAL CHELATION; LONG-TERM EFFICACY; QUALITY-OF-LIFE; PEDIATRIC-PATIENTS; MYELODYSPLASTIC SYNDROMES; COMBINED DEFERIPRONE; COMBINATION THERAPY;
D O I
10.1155/2022/4911205
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Patients suffering from iron overload can experience serious complications. In such patients, various organs, such as endocrine glands and liver, can be damaged. Although iron is a crucial element for life, iron overload can be potentially toxic for human cells due to its role in generating free radicals. In the past few decades, there has been a major improvement in the survival of patients who suffer from iron overload due to the application of iron chelation therapy in clinical practice. In clinical use, deferoxamine, deferiprone, and deferasirox are the three United States Food and Drug Administration-approved iron chelators. Each of these iron chelators is well known for the treatment of iron overload in various clinical conditions. Based on several up-to-date studies, this study explained iron overload and its clinical symptoms, introduced each of the above-mentioned iron chelators, and evaluated their advantages and disadvantages with an emphasis on combination therapy, which in recent studies seems a promising approach. In numerous clinical conditions, due to the lack of accurate indicators, choosing a standard approach for iron chelation therapy can be difficult; therefore, further studies on the issue are still required. This study aimed to introduce each of these iron chelators, combination therapy, usage doses, specific clinical applications, and their advantages, toxicity, and side effects.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] The evolution of iron chelators for the treatment of iron overload disease and cancer
    Kalinowski, DS
    Richardson, DR
    PHARMACOLOGICAL REVIEWS, 2005, 57 (04) : 547 - 583
  • [2] EVALUATION OF POLYMERIC HYDROXAMIC ACID IRON CHELATORS FOR TREATMENT OF IRON OVERLOAD
    WINSTON, A
    VARAPRASAD, DVPR
    METTERVILLE, JJ
    ROSENKRANTZ, H
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1985, 232 (03): : 644 - 649
  • [3] Orally active Chelators for the treatment of iron overload diseases
    Chin, AP
    Bernhardt, PV
    Richardson, DR
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2003, 96 (01) : 118 - 118
  • [4] Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia
    Vichinsky, Elliott
    PEDIATRICS, 2008, 121 (06) : 1253 - 1256
  • [5] EFFECTS OF IRON CHELATORS AND IRON OVERLOAD ON SALMONELLA INFECTION
    JONES, RL
    PETERSON, CM
    GRADY, RW
    KUMBARACI, T
    CERAMI, A
    GRAZIANO, JH
    NATURE, 1977, 267 (5606) : 63 - 65
  • [6] ERYTHROPOIETIN VERSUS IRON CHELATORS IN ANEMIA AND IRON OVERLOAD
    VREUGDENHIL, G
    VANHERPEN, C
    KOENE, RAP
    NETHERLANDS JOURNAL OF MEDICINE, 1993, 42 (1-2): : 45 - 47
  • [7] Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity
    Bernhardt, Paul V.
    Chin, Piao
    Sharpe, Philip C.
    Richardson, Des R.
    DALTON TRANSACTIONS, 2007, (30) : 3232 - 3244
  • [8] Coordination chemistry and biology of chelators for the treatment of iron overload disorders
    Bernhardt, Paul V.
    DALTON TRANSACTIONS, 2007, (30) : 3214 - 3220
  • [9] IRON CHELATORS IN NANOFORMULATIONS FOR SPECIFIC TARGETING AND EFFECTIVE REMOVAL OF MACROPHAGE IRON FOR TREATMENT OF IRON OVERLOAD DISEASES
    Nie, Guangjun
    Guo, Shanshan
    Liu, Gang
    Anderson, Greg
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) : E230 - E230
  • [10] Iron overload in myelodysplastic syndromes.: Role of iron chelators
    Hernández, AA
    MEDICINA CLINICA, 2005, 124 (17): : 654 - 655